Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump

Merck has rallied about 20% over the past month after a string of positive clinical and commercial developments, including a near-term stock pop following encouraging data; its $11.5 billion 2021 Acceleron buy has produced sotatercept (Winrevair), which is approved for PAH, generated $360 million in Q3 sales and met the primary endpoint in a phase 2 study for CpcPH due to HFpEF (a rare, unmet indication that will require phase 3 confirmation). The company also reported positive phase 2/3 data for raludotatug deruxtecan in ovarian cancer (Breakthrough Therapy Designation), is awaiting approval for a new HIV combination, acquired Cidara for an influenza candidate and launched the Capvaxive pneumonia vaccine, underscoring active pipeline replenishment ahead of Keytruda’s critical 2028 U.S. patent cliff (Keytruda: $29.5 billion, ~46% of 2024 revenue). While the Keytruda exclusivity loss poses a material medium-term headwind, Merck’s growing approved franchises, late-stage assets, a potential subcutaneous Keytruda formulation and a strong dividend make it an attractive long-term, income-oriented investment contingent on successful phase 3 results and regulatory outcomes.

Analysis

Merck's shares have rebounded roughly 20% over the past month, with a near-4% single-day pop following encouraging clinical data; the rally is anchored by the payoff from the company's $11.5 billion 2021 Acceleron acquisition, which produced sotatercept (Winrevair) now approved for pulmonary arterial hypertension and generating $360 million in Q3 sales. Winrevair also met the primary endpoint in a phase 2 study for combined post- and precapillary pulmonary hypertension (CpcPH) due to HFpEF, an unserved indication with an addressable population under the U.S. rare-disease threshold (<200,000) that still requires confirmatory phase 3 trials before label expansion and commercial upside can be realized. Merck reported additional pipeline momentum with positive phase 2/3 results and Breakthrough Therapy Designation for raludotatug deruxtecan in ovarian cancer, a pending HIV combo approval, the Capvaxive pneumonia vaccine launch, and the Cidara acquisition to bolster an influenza program—all deliberate moves to diversify revenue ahead of Keytruda's U.S. patent expiry in 2028. Keytruda remains a material medium-term risk ( ~$29.5 billion in 2024 sales, ~46% of revenue), but Merck's subcutaneous Keytruda formulation, expanding approvals and a strong dividend program provide partial mitigation; primary near-term risks are regulatory outcomes and execution of planned phase 3 studies, which will drive volatility and determine how much of the recent share gain is sustainable.

Key Decisions for Investors

• Consider a measured buy for long-term, income-oriented portfolios given diversified late-stage pipeline progress and a solid dividend, but avoid overconcentration given Keytruda's 2028 patent cliff
• Monitor upcoming phase 3 readouts for Winrevair in CpcPH and regulatory milestones for raludotatug deruxtecan and the HIV combo and only materially add to positions after positive confirmatory data or approvals
• Maintain position-sizing discipline or use hedges ahead of 2028 exclusivity loss and track quarterly Winrevair sales trends (compare to $360 million in Q3) and progress on the subcutaneous Keytruda formulation as key indicators that mitigate medium-term revenue risk